In addition, the administration of BM-MSCs that overexpress ICAM-1 in a murine model of inflammatory bowel disease results in decreased lesions, which is associated with a decrease in the frequency of Th1 and Th17 cells, an increase in regulatory T cells, decreased transcription of IFN-γ and Il-17, and increased transcription of Foxp3 [62]. Here, IL17A is linked to inflammatory bowel disease.